INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Morphic Holding
(MORF) announced a definitive agreement for Lilly to acquire Morphic, a
biopharmaceutical company developing oral integrin therapies for treatment of
serious chronic diseases. Lilly will commence a tender offer to acquire all
outstanding shares of Morphic for a purchase price of $57 per share in cash or
an aggregate of approximately $3.2 billion.

Morphic is a biopharmaceutical company developing a portfolio of oral integrin
therapies for the treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and cancer.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX